MedTrace Logo

Clinical Trial to Evaluate the Efficacy of Food Supplement Manremyc® Against SARS- COV-2 Infection (COVID-19) in Healthcare Workers

NCT04452773 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 315

Last updated 2020-07-15

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy of Manremyc® food supplement for reduce the incidence of SARS-CoV-2 infection in a high risk population, as healthcare workers.

Conditions

  • COVID19

Interventions

DIETARY_SUPPLEMENT

Manremyc

Manremyc is composed by 10E5 heat-inactivated Mycobacterium s. manresensis bacilli

DIETARY_SUPPLEMENT

Placebo

Same excipients than active arm without bacilli.

Sponsors & Collaborators

  • Reig Jofre Group

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-14
Primary Completion
2020-09-30
Completion
2021-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04452773 on ClinicalTrials.gov